Cardio Diagnostics Holdings Inc. has announced a new clinical study in collaboration with AGEPHA Pharma to investigate a precision-guided approach to managing inflammation-driven coronary heart disease $(CHD)$. AGEPHA Pharma will provide LODOCO® (low-dose colchicine), an FDA-approved anti-inflammatory medication, for the study. The research will utilize Cardio Diagnostics' PrecisionCHD™ blood test to identify patients with inflammation-driven CHD and evaluate their response to LODOCO® over time. The study aims to use DNA methylation signatures to monitor changes in inflammation. Cardio Diagnostics is currently in the process of selecting clinical sites for the study, which will be registered as a clinical trial. Results of the study have not yet been presented and will be shared in the future upon completion of the trial.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。